News: This New Covid Vaccine Could Bring... (The New York Times) - Behind the headlines
In the news
Media coverage of health and science topics
Behind the headlines
Research findings and data from the National Library of Medicine
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
Two 1 μg or 2 μg doses of CV7202 were well tolerated and elicited rabies neutralizing antibody responses that met WHO criteria in all recipients, but 5 μg had unacceptabl …
People also viewed
A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19CureVac AG
This study aims to: - Demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants. - Demonstrate the efficacy …NCT04652102
- December 1, 2020
- February 26, 2021
Also of interest
Additional recent and related news
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Scientists developed a SARS-CoV-2 vaccine by adding a key coronavirus gene to the measles vaccine.
If approved by the FDA, Pfizer and BioNTech’s mRNA vaccine would be the first of its kind, setting a record for speed—but raising questions about distribution.